As part of the cooperation agreement, the Pharmasyntez Group, with the support of the St Petersburg Government, is implementing an investment project – the launch of the fourth stage of the pharmaceutical complex, which will expand the production of high-tech biological medicines and create more than 500 new jobs. Construction of the fourth stage of Pharmasyntez-Nord in the St. Petersburg SEZ on the Novoorlovskaya site will begin in 2026 and will have been completed by 2029. The total investment in the construction and development of the pharmaceutical plant in St Petersburg will be around 20 billion rubles by the time the fourth stage is completed.

Pharmasyntez-Nord JSC (part of the Pharmasyntez Group of Companies) is a world level modern pharmaceutical research and production complex specializing in the development and production of biotechnological medicines and drugs for the treatment of oncological, autoimmune diseases and diabetes mellitus. At present, Pharmasyntez-Nord produces 45 trade names of oncological drugs, 99% of which are included in the list of vital and essential drugs of the Ministry of Health of the Russian Federation.

Two stages of the pharmaceutical plant, employing 900 people, are now up and running. The plant is equipped with the equipment from the world's leading manufacturers and has its own R&D center on the site. The second production line was launched by Vladimir Putin, President of the Russian Federation, in March 2023. The company is currently in the active phase of the third stage of the plant construction, which will be completed in 2026.

Mikhail Kvasnikov, Chief Executive Officer of Pharmasyntez-Nord JSC, said:

“We are expanding production and gradually increasing capacity so that patients with complex diseases can receive modern, high-quality medicines from a domestic manufacturer. I am confident that our project will contribute to the development of the manufacturing potential of St Petersburg and the country as a whole.”